New Report Available: Moldova Pharmaceuticals & Healthcare Report Q3 2013
Moldova will not witness a sudden influx of multinational drugmakers. Combined with limited public sector healthcare resources, its low per capita incomes and thus pharmaceutical spending will continue to provide few opportunities for research-based pharmaceutical manufacturers, although we note that Moldova remains committed to healthcare modernisation and European integration.
View full press release